In short
MK-1200 is an investigational drug currently being studied in clinical trials for patients with advanced solid tumors. This article provides an overview of the ongoing research, including the study's objectives, eligibility criteria, and potential benefits for patients with certain types of cancer.
At a glance
- Drug Name
- MK-1200
- Trial Phase
- Phase 1/2
- Target Conditions
- Advanced solid tumors (gastric, esophageal, biliary tract, pancreatic ductal adenocarcinoma)
- Main Objective
- Evaluate safety and tolerability of MK-1200 monotherapy
- Key Secondary Objectives
- Assess antitumor activity, pharmacokinetics, objective response rate
- Administration Method
- Intravenous infusion
- Key Eligibility Criteria
- Confirmed advanced solid tumor, progressed on 1-2 prior therapies
- Primary Endpoints
- Number of participants with dose-limiting toxicities, adverse events, and treatment discontinuation due to adverse events
- Key Secondary Endpoints
- Objective response rate, duration of response, progression-free survival, overall survival
What is MK-1200?
MK-1200, also known as SKB315, is a new investigational drug being developed for the treatment of advanced solid tumors. It is classified as a biological product, which means it is derived from living organisms or contains components of living organisms. The drug is currently undergoing clinical trials to evaluate its safety and effectiveness in patients with specific types of advanced cancers.
What conditions does MK-1200 target?
MK-1200 is being studied for the treatment of advanced solid tumors. Specifically, the clinical trial is focusing on patients with the following types of cancer:
- Gastric cancer (including cancer of the gastroesophageal junction)
- Esophageal cancer
- Biliary tract cancer
- Pancreatic ductal adenocarcinoma
These cancers are considered advanced when they are unresectable (cannot be removed by surgery) and/or have metastasized (spread to other parts of the body).
Current Clinical Trial Information
MK-1200 is currently being evaluated in a Phase 1/2 clinical trial. This trial is designed to assess both the safety and efficacy of the drug. Here are some key points about the trial:
- It is an open-label study, which means both the researchers and participants know which treatment is being administered.
- The trial is divided into two parts: Part 1 and Part 2.
- The main objective is to evaluate the safety and tolerability of MK-1200 when used alone (monotherapy).
- Secondary objectives include assessing the drug's effectiveness in shrinking tumors and its effects on patient survival.
How MK-1200 Works
While the exact mechanism of action is not provided in the available information, we know that MK-1200 is a biological product. Biological drugs often work by targeting specific proteins or processes in cancer cells or by enhancing the body's immune response against cancer. The ongoing clinical trial will help researchers better understand how MK-1200 works in patients with advanced solid tumors.
Who is eligible for the MK-1200 trial?
The trial has specific inclusion and exclusion criteria. Some key eligibility factors include:
Inclusion Criteria:
- Confirmed advanced solid tumor of the types mentioned earlier
- Have received and progressed on 1 or 2 prior lines of therapy
- Recovered from side effects of previous cancer treatments
- HIV-positive patients may be eligible if their condition is well-controlled with antiretroviral therapy
Exclusion Criteria:
- Active severe digestive disease
- Known active brain metastases
- Active infections requiring systemic therapy
- History of hepatitis B or active hepatitis C
- Recent major surgery or cardiovascular events
- Uncontrolled diabetes or hypertension
- Recent anticancer treatments or radiation therapy
Safety and Efficacy Evaluation
The trial is designed to carefully assess both the safety and effectiveness of MK-1200. Key measures include:
Safety Assessments:
- Dose-limiting toxicities (DLTs): These are side effects severe enough to prevent increasing the dose of the drug.
- Adverse events (AEs): Any unfavorable medical occurrences during the trial.
- Number of participants who stop treatment due to side effects.
Efficacy Assessments:
- Objective response rate (ORR): The proportion of patients whose tumors shrink or disappear after treatment.
- Duration of response (DOR): How long the tumor response lasts.
- Progression-free survival (PFS): The time from start of treatment until the cancer progresses or the patient dies.
- Overall survival (OS): The time from start of treatment until death from any cause.
These outcomes will be assessed by both trial investigators and an independent review committee to ensure accuracy.
How is MK-1200 administered?
MK-1200 is given as an intravenous infusion. This means it is delivered directly into the bloodstream through a vein. The drug comes in the form of a powder that is made into a solution for infusion. The exact dosing schedule and duration of treatment will be determined as part of the clinical trial.